Form 4: Scotts Miracle-Gro Director Acquires Dividend Equivalent Rights

Sentiment:

SEC Form 4 Filing


Thomas N. Kelly Jr., a director at Scotts Miracle-Gro, acquired 80 dividend equivalent rights on March 8, 2024, linked to existing DSU or RSU grants.

Summary

  • On March 8, 2024, Thomas N. Kelly Jr., a director of Scotts Miracle-Gro Co, acquired 80 dividend equivalent rights.
  • These rights are associated with previously granted Deferred Stock Units (DSUs) or Restricted Stock Units (RSUs).
  • The dividend equivalent rights become exercisable proportionally with the DSUs or RSUs to which they relate.
  • Each dividend equivalent right represents the economic equivalent of one common share of Scotts Miracle-Gro.
  • The price of the dividend equivalent rights is $68.03.
  • Following the transaction, Kelly directly owns 324 dividend equivalent rights.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This specific transaction reflects the ongoing compensation and equity alignment strategies at Scotts Miracle-Gro.

Stakeholder Impact

  • The transaction has a minimal direct impact on stakeholders, as it involves the acquisition of dividend equivalent rights by a director as part of their compensation.

Key Dates

DateDescription
03/08/2024Date of transaction: Thomas N. Kelly Jr. acquired 80 dividend equivalent rights.
03/12/2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.